EP1915369A4 - Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène - Google Patents

Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène

Info

Publication number
EP1915369A4
EP1915369A4 EP06775086A EP06775086A EP1915369A4 EP 1915369 A4 EP1915369 A4 EP 1915369A4 EP 06775086 A EP06775086 A EP 06775086A EP 06775086 A EP06775086 A EP 06775086A EP 1915369 A4 EP1915369 A4 EP 1915369A4
Authority
EP
European Patent Office
Prior art keywords
leukotiiene
azolylmethyl
benzothiophene
indole
biosynthesis inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06775086A
Other languages
German (de)
English (en)
Other versions
EP1915369A1 (fr
Inventor
Carl Berthelette
Claude Dufresne
Lianhai Li
Zhaoyin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of EP1915369A1 publication Critical patent/EP1915369A1/fr
Publication of EP1915369A4 publication Critical patent/EP1915369A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP06775086A 2005-08-11 2006-08-08 Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène Withdrawn EP1915369A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70736205P 2005-08-11 2005-08-11
PCT/CA2006/001306 WO2007016784A1 (fr) 2005-08-11 2006-08-08 Nouveau 1,2,3-tπazolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu’inhibiteurs de biosynthèse leukotπène

Publications (2)

Publication Number Publication Date
EP1915369A1 EP1915369A1 (fr) 2008-04-30
EP1915369A4 true EP1915369A4 (fr) 2010-09-08

Family

ID=37727061

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06775086A Withdrawn EP1915369A4 (fr) 2005-08-11 2006-08-08 Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène

Country Status (5)

Country Link
EP (1) EP1915369A4 (fr)
JP (1) JP2009504575A (fr)
AU (1) AU2006279211A1 (fr)
CA (1) CA2618586A1 (fr)
WO (1) WO2007016784A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
IN2012DN00754A (fr) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
KR101875246B1 (ko) 2010-12-07 2018-07-05 아미라 파마슈티칼스 인코포레이티드 폴리시클릭 lpa₁ 길항제 및 그의 용도
PE20140879A1 (es) 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138797A1 (fr) 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. Composés à base de 3- ou 5-biphényl-4-ylisoxazole utiles pour le traitement de la fibrose, de la douleur, du cancer et de troubles respiratoires, allergiques, de troubles du système nerveux ou de troubles cardiovasculaires
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
ES2838977T3 (es) 2015-03-06 2021-07-02 Pharmakea Inc Inhibidores de la lisil oxidasa fluorada tipo 2 y usos de los mismos
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
WO2018048943A1 (fr) 2016-09-07 2018-03-15 Pharmakea, Inc. Formes cristallines d'un inhibiteur de lysyl oxydase de type 2 et leurs procédés de fabrication

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
AU2004245146B2 (en) * 2003-06-11 2010-01-21 Merck Frosst Canada Ltd 7-(1,3-thiazol-2-yl)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2007016784A1 *

Also Published As

Publication number Publication date
EP1915369A1 (fr) 2008-04-30
JP2009504575A (ja) 2009-02-05
AU2006279211A1 (en) 2007-02-15
CA2618586A1 (fr) 2007-02-15
WO2007016784A1 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
TWI369351B (en) 2,4-diamino-pyrimidines as aurora inhibitors
EP1915369A4 (fr) Nouveau 1,2,3-t ii azolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu'inhibiteurs de biosynthèse leukotiiène
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
PL1928840T3 (pl) 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
GB0505970D0 (en) Culture medium containing kinase inhibitor, and uses thereof
IL187620A0 (en) 17??-hsd1 and sts inhibitors
ZA200804489B (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP1951680A4 (fr) Nouveaux derives de 2-aminopyrimidinone et leur utilisation
IL187790A0 (en) Fk 228 derivatives as hdac inhibitors
IL195279A0 (en) 1,5-diphenylpyrazoles ii as hsp90 inhibitors
EP1946764A4 (fr) Composition nutritive
EP1962852A4 (fr) Composes, compositions et methodes
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
PL378587A1 (pl) Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
EP1908786A4 (fr) Préparation de 2-cyanoacrylate
GB0513888D0 (en) Core 2 GLCNAC-T Inhibitors II
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
HK1115878A1 (en) (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
EP1898940A4 (fr) Inhibiteurs d'integrine alpha2beta1/gpia-iia
GB0516245D0 (en) Process, composition and compound
EP1687399A4 (fr) Luciferase modifiee

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110308